91.1 F
San Fernando
Thursday, Mar 28, 2024

Takeda to Market Up to 13 Amgen Molecules in Japan

Takeda Pharmaceutical Company Limited will market up to 13 molecules from Amgen’s pipeline for the Japanese. As a result of the agreement, Japanese patients will now have access to Amgen’s medicines across a range of therapeutic areas, including oncology, inflammation and pain. Amgen will receive an upfront cash payment of $200 million. Takeda will also pay Amgen up to $340 million in expected worldwide development costs for the molecules over the next several years as well as $362 million in success-based milestone payments and double digit royalties on Japanese sales. Additionally, Takeda plans to acquire all the shares of Amgen’s Japanese subsidiary, Amgen KK. The share transaction is anticipated to close in the first quarter.

Featured Articles

Related Articles